Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for an audio catch-up of the past week's main biopharma events as brought to you by Scrip's global team, in this mini podcast version of Five Must-Know Things. 

This episode includes the main news from around the biopharma world in the business week ended 11 December 2020.

Important updates from the ASH meeting, the latest developments with COVID-19 vaccines, and new ambitions at Japan's largest pharma firm are all on the menu this time. 

Stories mentioned in this episode:

(Also see "ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place" - Scrip, 5 Dec, 2020.)

(Also see "ASH 2020: Novel CAR-T Approaches Chase BCMA-Targeting Frontrunners" - Scrip, 8 Dec, 2020.)

(Also see "J&J's Gorsky On Janssen's COVID-19 Vaccine Timeline, Scale-Up and Back Story" - Scrip, 7 Dec, 2020.)

(Also see "Last Minute Allocation Shake Up? Pfizer’s One-Dose Data Could Change COVID-19 Vaccine Rollout" - Scrip, 8 Dec, 2020.)

(Also see "Takeda Looks To Ride 'Wave 1' To JPY5tn Target" - Scrip, 8 Dec, 2020.)

These and all Informa Pharma Intelligence podcasts are available on SoundCloud, Apple Podcasts, TuneIn and Google Play and also via smart speakers - just make sure one of these providers is set up as your default for podcasts, and then ask for "Pharma Intelligence podcasts".




Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts